State-of-the-art expansion represents five-fold increase in probiotics production capacity
ADM (NYSE: ADM) announced today that it plans to construct a new, state-of-the-art facility in Valencia, Spain, that will expand its capabilities to meet growing demand for microbiome solutions.
“Our new Valencia facility will feature leading-edge technology and dramatically enhance our ability to meet fast-growing demand for products and solutions from nature designed to target the microbiome and help improve metabolic health,” said Ian Pinner, chief strategy and innovation officer, and president of ADM’s Health & Wellness division. “Consumers today are increasingly focusing on the foundational role food plays in supporting health and wellness, and our continued investment in these growth areas ensures that ADM is perfectly positioned to meet their needs.”
The new facility represents a five-fold increase in production capacity through ADM’s Biopolis, a leading provider of microbial technologies based in Spain. The facility will produce a wide array of science-based, innovative probiotics and postbiotics — using ADM’s industry-leading technology — to meet growing demand for new solutions for healthy weight management, skin health, immune health, gut health, oral health, fertility and more. It will be co-located with ADM’s flavor production facility in Valencia, and is expected to be online in 2022.
“Consumers today are thinking about the things they eat and drink in entirely new ways,” Pinner continued. “They expect food and beverages that are not only delicious, but support health and wellness, come from sustainable ingredients, and are produced by companies that share their values. The growth investments ADM has made in recent years put us in an unparalleled position to meet those changing needs. From alternative proteins, to our pantry of sustainable ingredients, flavors and colors, to our unequalled array of pre-, pro- and postbiotics, ADM is enriching lives around the globe.”
ADM is an established market leader for microbiome solutions with an award-winning portfolio of products and ingredients, including NutraIngredients’ 2020 ‘Probiotic Product of the Year’, ADM’s Bio-Kult Migréa®; 2020 Ingredient of the Year in the Weight Management category, ADM’s Bifidobacterium lactis BPL1; and the 2020 Editor’s Award winner for Functional Food Innovation, ADM’s Bacillus subtilis PXN®21®, a live microbial strain shown to reduce the aggregation of α-synuclein, paving the way for future research in Parkinson’s disease.
For more information about ADM’s functional health solutions, visit www.adm.com/functionalhealth.
At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over. Learn more at www.adm.com.
Coronavirus hospitalizations are growing in 37 states as Fauci warns the world not ‘on the road’ to ending pandemic yet
- Covid-19 hospitalizations were growing by 5% or more, based on a weekly average, in 37 states as of Sunday, according to a CNBC analysis of data collected by the Covid Tracking Project.
- Alaska, Iowa, Kentucky, Montana, Nebraska, Oklahoma, South Dakota, Utah, Wisconsin and West Virginia all hit record highs in the average of hospitalizations.
- Covid-19 hospitalizations, like the so-called positivity rate and deaths, are a key measure because they help scientists gauge the pandemic’s severity.
Coronavirus hospitalizations are growing in a majority of U.S. states as Dr. Anthony Fauci, the nation’s leading infectious disease expert, warns that the world is not yet “on the road” to ending the pandemic.
Coronavirus hospitalizations, like the so-called positivity rate and deaths ,are a key measure because they help scientists gauge the pandemic’s severity.
Covid-19 hospitalizations were growing by 5% or more in 37 states as of Sunday, according to a CNBC analysis of data collected by the Covid Tracking Project, an increase from 36 states a week earlier. Figures are based on a weekly averages to smooth out daily reporting.
Alaska, Iowa, Kentucky, Montana, Nebraska, Oklahoma, South Dakota, Utah, Wisconsin and West Virginia all hit record highs in the average of hospitalizations, the Covid Tracking Project data shows. The District of Columbia and Hawaii are the only two places where hospitalizations are declining, according to the data.
In Texas, where hospitalizations are growing, 6.71% of beds across its hospitals have Covid-19 patients as of Sunday, according to state data. In Wisconsin, 10.9% of its beds have Covid-19 patients, state data shows.
“What’s concerning here is that it’s only mid-October and there is a long fall and winter,” said Dr. Isaac Bogoch, an infectious disease specialist and professor at the University of Toronto.
“We are clearly in the second wave in many parts of the Northern Hemisphere and we really need to have more control of this infection at the community level,” he said. “We know exactly what it’s like when health-care systems are spread beyond capacity. We saw that in New York City. We saw that in Houston. We saw that in many other parts of the United States.”
The increase in hospitalizations comes after U.S. cases have grown in recent weeks following a late-summer lull. Over the past seven days, the country has reported an average of about 56,000 new cases per day, up more than 13% compared with a week earlier, according to a CNBC analysis of Johns Hopkins University data. That remains lower than the roughly 70,000 new cases a day the U.S. was reporting earlier this year but is higher than the roughly 30,000 cases per day in early September and is increasing.
U.S. health officials and infectious disease experts have repeatedly warned that the outbreak could get worse as temperatures cool and people begin to head
The global hemoglobin testing market size is poised to grow by USD 612.82 million during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201016005222/en/
Technavio has announced its latest market research report titled Global Hemoglobin Testing Market 2020-2024 (Graphic: Business Wire)
Globally, the prevalence of diabetes has significantly increased over the decades. This can be attributed to sedentary lifestyles, obesity, and lack of physical activity. The prevalence of diabetes is growing significantly in countries across the Middle East such as Iran, where around 24% of the people aged over 40 have diabetes. In the UAE, more than 16% of the total population aged 20-79 years had diabetes in 2019. The rising prevalence of diabetes has increased the demand for effective and advanced hemoglobin testing devices to monitor glucose levels, thereby driving the growth of the market.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
The major hemoglobin testing market growth came from the healthcare centers segment in 2019. This is due to the increasing number of hospitals in developing countries and the growing trend of medical tourism.
North America was the largest market for hemoglobin testing in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to the increasing prevalence of obesity and diabetes in the region.
The global hemoglobin testing market is fragmented. Abbott Laboratories, ACON Laboratories Inc., Bayer AG, Bio-Rad Laboratories Inc., Danaher Corp., Diazyme Laboratories Inc., EKF Diagnostics Holdings Plc, F. Hoffmann-La Roche Ltd., Siemens AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To help clients improve their market position, this hemoglobin testing market forecast report provides a detailed analysis of the market leaders.
As the business impact of COVID-19 spreads, the global hemoglobin testing market 2020-2024 is expected to have neutral growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: https://www.technavio.com/report/hemoglobin-testing-market-industry-analysis
Growing preference for home care settings will be a Key Market Trend
Over the years, the demand for homecare blood testing devices has increased across the globe. This is because home care testing devices provide faster results and help patients better manage their disease. They also reduce the overall investigation time and the number of visits to hospitals outpatient department and diagnostic laboratories. This has encouraged vendors in the market to offer a wide range of diagnostics devices that are ideal for home use. For instance, PTS